| Molecular Formula | C15H22N4O
|
| Molar Mass | 274.36 |
| Density | 1.176±0.06 g/cm3(Predicted) |
| Boling Point | 537.8±50.0 °C(Predicted) |
| pKa | 11.89±0.10(Predicted) |
| In vitro study | PF-06305591 (compound 9) has a highly attractive profile with respect to NaV selectivity, hERG activity, passive permeability and in vitro metabolic stability. |
| In vivo study | PF-06305591 (compound 9) has good rat bioavailability. PF-06305591 offers the possibility of investigating higher IC 50 multiples of Nav1.8 blockade in the clinic, and therefore a more thorough evaluation of the role of NaV1.8 in the treatment of pain. |